Loading...
Efficacy and safety of allogeneic hematopoietic stem cell transplantation in curing Sickle Cell Disease: A systematic review and meta-analysis of single-arm studies
Folarin, Moteleola Al-Zubaidi, Hanaan Moore, Emma Eze, Ukpai Palanisamy, Navaneethan
Folarin, Moteleola
Al-Zubaidi, Hanaan
Moore, Emma
Eze, Ukpai
Palanisamy, Navaneethan
Citations
Altmetric:
Advisors
Editors
Other Contributors
Affiliation
EPub Date
Publication Date
2025-09-13
Submitted Date
Collections
Files
Loading...
Published version
Adobe PDF, 2.49 MB
Other Titles
Abstract
Sickle cell disease (SCD) is a life-threatening hemolytic genetic disorder affecting approximately 20 to 25 million people globally. Conventional treatment, like hydroxyurea, is supportive but not a cure. Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) has gained popularity recently as it offers a potential cure for SCD. Although several independent studies exist supporting this, there is a lack of consolidated evidence for a more comprehensive analysis of clinical outcomes. In this systematic review and meta-analysis, we assessed the safety and efficacy of allo-HSCT in SCD, offering information on results for various age groups, donor types, conditioning procedures/regimens, and stem cell sources. A systematic literature search was carried out in PubMed and Scopus for articles published between January 2010 and March 2025. Articles that satisfied the inclusion requirements were subjected to quality assessment using the Newcastle-Ottawa Scale (NOS). Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines were followed throughout. Statistical analyses were performed using meta, an R package. The meta-analysis of 58 studies (n = 7931) revealed allo-HSCT to have 94%, 86%, 20%, 14%, 9%, 6% for overall survival (OS), event-free survival (EFS), acute graft-versus-host disease (aGVHD), chronic graft-versus-host disease (cGVHD), graft-failure (GF), and mortality, respectively, in SCD. Subgroup analysis demonstrated that clinical outcomes varied based on the type of donors, conditioning procedures/regimens and stem cell sources. The findings of this study show that allo-HSCT is safe and efficacious in curing SCD with an OS of 94%. GF and GVHD issues could be reduced by following personalized conditioning regimens/post-transplantation prophylaxis.
Citation
Folarin, M., Al-Zubaidi, H., Moore, E., Eze, U., Palanisamy, N. (2026). Efficacy and safety of allogeneic hematopoietic stem cell transplantation in curing Sickle Cell Disease: A systematic review and meta-analysis of single-arm studies. Transplantation and Cellular Therapy, 32(1), article-number 100.e1-100.e23. https://doi.org/10.1016/j.jtct.2025.09.023
Publisher
Elsevier
Journal
Transplantation and Cellular Therapy
Research Unit
PubMed ID
PubMed Central ID
Type
Article
Language
en
Description
© 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.
Series/Report no.
ISSN
EISSN
2666-6367
ISBN
ISMN
Gov't Doc
Test Link
Sponsors
Unfunded